Get the Stockscreener App
41.86
0.71%
-0.30
After Hours:
41.86
Qiagen Nv stock is traded at $41.86, with a volume of 1.82M.
It is down -0.71% in the last 24 hours and up +1.04% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$42.16
Open:
$43.055
24h Volume:
1.82M
Relative Volume:
1.38
Market Cap:
$9.32B
Revenue:
$1.97B
Net Income/Loss:
$92.93M
P/E Ratio:
102.95
EPS:
0.4066
Net Cash Flow:
$459.60M
1W Performance:
-2.94%
1M Performance:
+1.04%
6M Performance:
-7.00%
1Y Performance:
-6.61%
1-Day Range:
$41.73
$43.26
1-Week Range:
$41.73
$43.46
52-Week Range:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
41.86 | 9.32B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Analysts Are Updating Their Qiagen N.V. (NYSE:QGEN) Estimates After Its First-Quarter Results - simplywall.st
Is Qiagen (NYSE:QGEN) A Risky Investment? - simplywall.st
Qiagen N.V. (NYSE:QGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
QIAGEN Reports Strong Q1 2025 Results and Plans Dividend Initiation - TipRanks
QIAGEN NV : UBS sticks Neutral - marketscreener.com
QIAGEN Reports Strong Q1 2025 Earnings - TipRanks
Qiagen: Good start to 2025 - marketscreener.com
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR - GlobeNewswire Inc.
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up - TradingView
QIAGEN NV : Gets a Buy rating from Deutsche Bank - marketscreener.com
Qiagen: Q1 Earnings Snapshot - Norwalk Hour
QiagenH. Rusckowski To Succeed Lawrence A. Rosen As Chairman Of Supervisory Board Following AGM - marketscreener.com
QIAGEN announces plans for transition in leadership of Supervisory Board - BioSpace
Qiagen N : QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase - marketscreener.com
Qiagen N : QIAGEN announces plans for transition in leadership of Supervisory Board - marketscreener.com
QIAGEN announces plans for transition in leadership of Superviso - GuruFocus
Stephen Rusckowski to Take Over as Chairman at Qiagen (QGEN) | Q - GuruFocus
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings - Yahoo Finance
Qiagen NV reports results for the quarter ended March 31Earnings Summary - TradingView
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Qiagen board to elect Rusckowski chairman - TipRanks
Qiagen Q1 Adjusted Earnings, Revenue Rise; New $500 Million Stock Buyback Planned - marketscreener.com
QIAGEN (QGEN) Surpasses Q1 Revenue Forecasts, Highlights Strategic Growth | QGEN Stock News - GuruFocus
Stephen Rusckowski to Take Over as Chairman at Qiagen (QGEN) | QGEN Stock News - GuruFocus
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase | QGEN Stock News - GuruFocus
Qiagen (QGEN) Announces Supervisory Board Transition - StreetInsider
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase - Stock Titan
QIAGEN to propose annual cash dividend for shareholder vote By Investing.com - Investing.com South Africa
Qiagen N : QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting - marketscreener.com
Qiagen Plans to Initiate Dividend Payments - marketscreener.com
Qiagen NV (QGEN) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting | QGEN Stock News - GuruFocus
Qiagen N.V. Proposes Initiation of Annual Cash Dividend, Payable on July 10, 2025 - marketscreener.com
Qiagen To Propose Initiation Of Annual Cash Dividend At AGM - marketscreener.com
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth - ADVFN
Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Qiagen NV expected to post earnings of 50 cents a shareEarnings Preview - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value - NBC4 Washington
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
RNA Editing Market Deep Research 2025-2032 | QIAGEN N.V., ProQR - openPR.com
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control - 01net
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term - Yahoo Finance
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million - ADVFN
QIAGEN NV : UBS reiterates its Neutral rating - marketscreener.com
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 | QGEN Stock News - GuruFocus
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 - Yahoo Finance
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 33% Undervaluation? - Yahoo Finance
QIAGEN N.V. Prepares to Release 2024 Financial Reports - TipRanks
PTA-AFR: QIAGEN N.V.: Pre-announcement of a financial report according to articles 114117 WpHG - TradingView
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):